Figure 1.

Fifty-four-year-old female with biopsy proven ALK-positive non-small cell lung cancer. (A) Initial chest CT shows a right lower lobe mass with associated pleural metastases and malignant pleural effusion. There is also nodular septal thickening and ground-glass opacities in the lower lobes consistent with lymphangitic carcinomatosis; (B) follow-up chest CT 2 months following initiation of ALK-targeted tyrosine kinase inhibitor shows marked treatment response with decreased size of primary lung mass and improvement of associated pleural metastases and lymphangitic carcinomatosis. ALK, anaplastic lymphoma kinase.